SCIE期刊CANCER IMMUNOLOGY IMMUNOTHERAPY 2024/2025影响因子:4.605 (CANCER IMMUNOL IMMUN) (0340-7004). (IMMUNOLOGY)(免疫学)Science

显示全部楼层 · 发表于 2025-3-23 13:03:51

Submitted on: 17 October 1999. Revised on: 20 January 2000. Accepted on: 08 February 2000. ___________________CANCER IMMUNOLOGY IMMUNOTHERAPY

显示全部楼层 · 发表于 2025-3-23 14:21:41

显示全部楼层 · 发表于 2025-3-23 18:04:16

显示全部楼层 · 发表于 2025-3-24 00:59:30

Submitted on: 13 November 2000. Revised on: 19 February 2001. Accepted on: 30 March 2001. ___________________CANCER IMMUNOLOGY IMMUNOTHERAPY

显示全部楼层 · 发表于 2025-3-24 03:46:18

Submitted on: 24 August 2009. Revised on: 24 October 2009. Accepted on: 25 November 2009. ___________________CANCER IMMUNOLOGY IMMUNOTHERAPY

显示全部楼层 · 发表于 2025-3-24 07:53:32

显示全部楼层 · 发表于 2025-3-24 13:32:02

Submitted on: 28 April 2016. Revised on: 04 August 2016. Accepted on: 16 September 2016. ___________________CANCER IMMUNOLOGY IMMUNOTHERAPY

显示全部楼层 · 发表于 2025-3-24 18:02:35

显示全部楼层 · 发表于 2025-3-24 20:08:59

显示全部楼层 · 发表于 2025-3-25 02:36:09

Submitted on: 27 February 2024. Revised on: 05 June 2024. Accepted on: 28 July 2024. ___________________CANCER IMMUNOLOGY IMMUNOTHERAPY

		自动登录	找回密码
密码			To register

关于派博传思			派博传思旗下网站			友情链接
派博传思介绍	公司地理位置	论文服务流程	影响因子官网	SITEMAP	大讲堂	北京大学	Oxford Uni.	Harvard Uni.
发展历史沿革	期刊点评	投稿经验总结	SCIENCEGARD	IMPACTFACTOR	派博系数	清华大学	Yale Uni.	Stanford Uni.
\|Archiver\|手机版\|小黑屋\| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-14 06:11
Copyright © 2001-2015 派博传思京公网安备110108008328 版权所有 All rights reserved